UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.